Compare Li Auto Inc (LI) vs Moderna, Inc. (MRNA) Price & Performance

Li Auto IncTrade

Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Li Auto Inc vs Moderna, Inc. — how do they compare? Li Auto Inc trades at $12.62 (market cap $12.54B), while Moderna, Inc. trades at $60.83 (market cap $23.88B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.

	LI	MRNA
Market Cap	$12.54B	$23.88B
Sector	Consumer Cyclical	Health
52-Week High	$26.69	$81.80
52-Week Low	$11.74	$22.36
Enterprise Value	$1.37B	$20.03B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

Klépierre reports 286.9M shares and voting rights as of July 31, 2026, with a €21.8B shopping mall portfolio.Na · 4 days agoNeutral Klépierre reports total shares and voting rights as of July 31, 2026, with upcoming Q3 activity update on October 21.Na · 4 days agoNeutral View details →

MRNA

New report analyzes 1,350+ precision medicine deals from 2019-2026, revealing market trends and deal structures.Researchandmarkets.Com · 4 days agoNeutral Global influenza vaccine market to grow to $13.32B by 2030, driven by aging population and vaccine innovationsResearchandmarkets.Com · 4 days agoNeutral View details →

About Li Auto Inc

Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.